PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Delafloxacin→

Delafloxacin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
189279-58-1
Molecular formula
C18H12ClF3N4O4
Molecular weight
440.8 g/mol
Drug class
Fluoroquinolone antibacterialDNA gyrase and topoisomerase IV inhibitor
Mechanism of action
Inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication, transcription and repair, producing bactericidal activity against susceptible Gram-positive and Gram-negative organisms.
Indications / reported uses
  • Treatment of acute bacterial skin and skin-structure infections in adults caused by susceptible bacteria, including MRSA
  • Treatment of community-acquired bacterial pneumonia in adults caused by susceptible pathogens under the applicable product label

Sources: US DailyMed — BAXDELA (delafloxacin) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Delafloxacin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Delafloxacin Permitted Daily Exposure (PDE) report (the Delafloxacin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Delafloxacin Occupational Exposure Limit (OEL) report (the Delafloxacin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.